Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
NCT05148195 (ESMO2023) Manual | Phase 2 | Microsatellite Stable Colorectal Carcinoma | Colorectal Cancer Second line TP53 mutation | KRAS | PI3KCA ... View more | 20 | (yrezgwnvmm) = xotlqpbhpo yqabyxkhhy (kgjolcfjtt, 8.7 - 49.1) View more | Positive | 22 Oct 2023 | |
NCT05148195 (ESMO2023) Manual | Phase 2 | Hepatocellular Carcinoma Second line | 20 | Suvemcitug+envafolimab | (gdtlxefced) = woqknjcnqv qstkqbibig (zivaippjir ) View more | Positive | 23 Oct 2023 |